Clinical efficacy of femtosecond laser for myopia
A systematic review protocol of randomized controlled trial
Xiao-fang Wang, MMa, Jun-xia Zhang, MMb,a*

Abstract
Background: Femtosecond laser (FL) is an effective method to treat patients with myopia, but its relative efficacy and safety is still unclear. Thus, this study will be conducted to assess the efficacy and safety of FL for myopia systematically.

Methods: This study will systematically retrieve the following electronic databases up to the present: Cochrane Library, PubMed, EMBASE, Web of Science, PsycINFO, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, Wanfang, VIP, and China National Knowledge Infrastructure. All electronic databases will be searched without any limitations of language and publication status. RevMan 5.3 software will be utilized for statistical analysis.

Results: We will summarize the targeted results evaluating the efficacy and safety of FL for patients with myopia.

Conclusions: This study will provide a comprehensive evidence summary on FL for patients with myopia. PROSPERO registration number: PROSPERO CRD42019148659.

Abbreviations: FL = femtosecond laser, RCTs = randomized controlled trials.

Keywords: efficacy, femtosecond laser, myopia, safety

1. Introduction

Myopia is a very common and yet perplexing ocular vision-threatening disorder.1–3 Its prevalence is increasing around the world annually.4–6 Its complications are often associated with high costs.4,7–10 Previous studies have found that it can be traced back to the childhood of school age onset myopia.6,11,12 Thus, it is very important to control and treat myopia as early as possible.13–15 Although several treatments are responsible for its management, its mechanism is still poorly understood.16 Femtosecond laser (FL) is reported to treat myopia effectively and safely.17–26 However, its results are still inconsistent. Therefore, this study will aim to assess the efficacy and safety of FL for patients with myopia.

2. Methods

2.1. Eligibility criteria

2.1.1. Types of studies. Randomized controlled trials (RCTs) assessing the efficacy and safety of FL for patients with myopia will be included. We will exclude nonclinical studies, noncontrolled trials, and non-RCTs.

2.1.2. Types of interventions. In the experimental group, all patients received any forms of FL will be included. In the control group, we will include all patients who have undergone any interventions, but not FL.

2.1.3. Types of participants. Participants with clinical diagnosis of myopia will be considered for inclusion without any restrictions of race, sex, age, and their economic sources.

2.1.4. Types of outcome measurements. The primary outcome is myopia progression, as assessed by cycloplegic autorefraction. The secondary outcomes are uncorrected distance visual acuity, corrected distance visual acuity, axial length, vision stability, refraction, contrast sensitivity, and adverse events.

2.2. Search strategy

2.2.1. Electronic databases sources. We will systematically perform a literature records search from the following electronic databases up to the present: Cochrane Library, PubMed, EMBASE, Web of Science, PsycINFO, Allied and Complementary Medicine Database, Chinese Biomedical Literature Database, Wanfang, VIP, and China National Knowledge Infrastructure. All electronic databases will be searched with no limitations of language and publication status. The sample of search strategy for Cochrane Library is presented in Table 1. Similar search strategy for other electronic databases will be adapted.

2.2.2. Other literature sources. We will also search dissertations, ongoing trials, conference abstracts, and reference lists of relevant reviews.
Table 1
Search strategy utilized in Cochrane Library.

| Number | Search terms |
|--------|--------------|
| 1      | MeSH descriptor: (myopia) explode all trees |
| 2      | (near-sightedness) or [short-sightedness] or [near-sight] or [near-sighted] or [near-sightedness] or [short-sight] or [short-sighted] or [short-sightedness] or [refractive error]: title, abstract, keywords |
| 3      | Or 1–2 |
| 4      | MeSH descriptor: (lasers) explode all trees |
| 5      | ([femtosecond laser] or [femtosecond lasers] or [infrared laser] or [ultrafast lasers] or [ultrashort pulse lasers] or [picosecond lasers]): title, abstract, keywords |
| 6      | Or 4–5 |
| 7      | MeSH descriptor: (randomized controlled trials) explode all trees |
| 8      | MeSH descriptor: (clinical trials as topic) explode all trees |
| 9      | ([random] or [randomly] or [blind] or [allocation] or [control] or [placebo] or [trial] or [clinical study] or [controlled study]): title, abstract, keywords |
| 10     | Or 6–9 |
| 11     | 3 and 6 and 10 |

MeSH, medical subject headings.

2.3. Study selection
We will screen the titles and abstracts independently by 2 authors according to the eligibility criteria, and any irrelevant studies will be excluded. The remaining studies will be read for full-text assessment. Any divergences regarding the study selection between 2 authors will be solved by a third author via consensus. Details of study selection are shown in the flowchart.

2.4. Data extraction
All essential data information will be extracted by 2 independent authors from each eligible study using standard data extraction sheet. It comprises of the following information: title, year of publication, country, patient characteristics, study objective, study setting, study design, randomization, blinding, concealment, sample size, follow-up information, treatment details, comparators, outcome measurements, and safety. Any discrepancies of data extraction between 2 authors will be resolved by a third author.

2.5. Assessment of risk of bias
Cochrane risk of bias tool is utilized for methodological quality assessment for each eligible study according to the Cochrane Handbook for Systematic Review of Interventions. Two authors will independently assess the risk of bias, and any discrepancies will be reached by a third author via consensus.

2.6. Missing data management
If there are missing or incomplete data for the primary results, original corresponding authors will be contacted to require those data. If that information cannot be obtained, only available data will be performed.

2.7. Measurements of treatment effect
Continuous outcome data will be measured using mean difference or standardized mean difference and 95% confidence intervals. Dichotomous outcome data will be presented as risk ratio and 95% confidence intervals.

2.8. Assessment of heterogeneity
We will identify heterogeneity among eligible studies using I² test. We defined that: I² ≤ 50% is low heterogeneity, and a fixed-effect model will be applied; and I² > 50% is substantial heterogeneity, and a random-effect model will be used.

2.9. Subgroup analysis
A subgroup analysis will be performed to identify the source of heterogeneity based on the different treatments, controls, and outcomes.

2.10. Sensitivity analysis
A sensitivity analysis will be conducted to find out the stability and robustness of outcome results by removing studies with high risk of bias.

2.11. Reporting bias
Funnel plot and Egger regression test[27,28] will be carried out to check any publication bias if more than 10 eligible studies will be included.

2.12. Data synthesis
Statistical analysis will be performed using RevMan 5.3 software. We will synthesize the data for each outcome measurement with similar study design, participants, interventions, and comparators. If low heterogeneity (I² < 50%) exists, we will perform meta-analysis. Otherwise, if high heterogeneity (I² > 50%) exists, we will conduct subgroup analysis. If there is still substantial heterogeneity after subgroup analysis, data pooling is deemed inappropriate, and we will report a qualitative discussion and a narrative description.

3. Discussion
At present, the therapeutic efficacy of FL on myopia is satisfactory. However, its efficacy of evidence-based medicine literature is still inconclusive. This study will systematically evaluate the efficacy and safety of FL for patients with myopia. The results of this study will summarize the latest evidence on assessing efficacy and safety of FL for myopia. They will also provide helpful evidence for patients, clinician, as well as for the policy-makers.

Author contributions
Conceptualization: Xiao-fang Wang, Jun-xia Zhang.
Data curation: Xiao-fang Wang, Jun-xia Zhang.
Formal analysis: Xiao-fang Wang.
Investigation: Jun-xia Zhang.
Methodology: Xiao-fang Wang.
Project administration: Jun-xia Zhang.
Resources: Xiao-fang Wang.
Software: Xiao-fang Wang.
Supervision: Jun-xia Zhang.
Validation: Xiao-fang Wang, Jun-xia Zhang.
Visualization: Xiao-fang Wang, Jun-xia Zhang.
Writing – original draft: Xiao-fang Wang.
Writing – review & editing: Xiao-fang Wang, Jun-xia Zhang.

References
[1] Cooper J, Tkatchenko AV. A review of current concepts of the etiology and treatment of myopia. Eye Contact Lens 2018;44:231–47.
[2] Coppola M, Rabolio A, Ciambelli MV, et al. Vitrectomy in high myopia: a narrative review. Int J Retina Vitreous 2017;3:37.
[3] Li J, Zhang Q. Insight into the molecular genetics of myopia. Mol Vis 2017;23:1048–80.
[4] de Jong PT. Myopia: its historical contexts. Br J Ophthalmol 2018;102:1021–7.
[5] Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016;123:1036–42.
[6] Greene PR, Greene JM. Advanced myopia, prevalence and incidence analysis. Int Ophthalmol 2018;38:869–74.
[7] Vitale S, Crotch MF, Sperduto R, Ellwein L. Costs of refractive correction of distance vision impairment in the United States, 1999-2002. Ophthalmology 2006;113:2163–70.
[8] Javitt JC, Chiang YP. The socioeconomic aspects of laser refractive surgery. Arch Ophthalmol 1994;112:1526–30.
[9] Kempen JH, Mitchell P, Lee KE, et al. Eye Diseases Prevalence Research Group The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol 2004;122:495–505.
[10] Flitcroft DI. The complex interactions of retinal, optical and environmental factors in myopia aetiology. Prog Retin Eye Res 2012;31:622–60.
[11] Luo HD, Gazzard G, Liang Y, et al. Defining myopia using refractive error and uncorrected logMAR visual acuity >0.3 from 1334 Singapore school children ages 7–9 years. Br J Ophthalmol 2006;90:562–6.
[12] Rudnicka AR, Kapetanakis VV, Warthun AK, et al. Global variations and time trends in the prevalence of childhood myopia, a systematic review and quantitative meta-analysis: implications for aetiology and early prevention. Br J Ophthalmol 2016;100:882–90.
[13] Leo SW. Scientific Bureau of World Society of Paediatric Ophthalmology and Strabismus (WSPOS). Current approaches to myopia control. Curr Opin Ophthalmol 2017;28:267–75.
[14] Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res 2018;62:134–49.
[15] Chassine T, Villain M, Hamel CP, Dahan V. How can we prevent myopia progression? Eur J Ophthalmol 2015;25:280–5.
[16] Sychev AA. Myopia in schoolchildren, its causes and mechanism of development. Gig Sanit 1981;83–6.
[17] Montés-Micó R, Rodríguez-Galítero A, Alió JL. Femtosecond laser versus mechanical keratome LASIK for myopia. Ophthalmology 2007;114:62–8.
[18] Sánchez-Pina JM, Arranz-Márquez E, Gil Ciganda N, et al. LASIK results of IntraLase femtosecond laser to correct myopia: efficacy, security and predictability. Arch Soc Esp Oftalmol 2007;82:423–8.
[19] Blum M, Kunert K, Gille A, Sekundo W. LASIK for myopia using the Zeiss VisuMax femtosecond laser and MEL 80 excimer laser. J Refract Surg 2009;25:350–6.
[20] Li H, Sun T, Wang M, Zhao J. Safety and effectiveness of thin-flap LASIK using a femtosecond laser and microkeratome in the correction of high myopia in Chinese patients. J Refract Surg 2010;26:99–106.
[21] Rodriguez-Galítero A, Martínez JV, Del Buey A, et al. Use of brimonidine before LASIK with femtosecond laser-created flaps for the correction of myopia: a contralateral eye study. J Refract Surg 2010;26:28–32.
[22] Albarrán-Diego C, Muñoz C, Ferrer-Blasco T, et al. Foldable iris-fixed phakic intraocular lens vs femtosecond laser-assisted LASIK for myopia between -6.00 and -9.00 diopters. J Refract Surg 2012;28:380–6.
[23] Ganesh S, Gupta R. Comparison of visual and refractive outcomes following femtosecond laser-assisted lasik with smile in patients with myopia or myopic astigmatism. J Refract Surg 2014;30:390–6.
[24] Kameyama K, Shimazu K, Igarashi A, Kobashi H. Effect of femtosecond laser setting on visual performance after small-incision lenticule extraction for myopia. Br J Ophthalmol 2015;99:1381–7.
[25] Liu M, Chen Y, Wang D, et al. Clinical outcomes after SMILE and femtosecond laser-assisted LASIK for myopia and myopic astigmatism: a prospective randomized comparative study. Cornea 2016;35:210–6.
[26] Hashemi H, Ghaffari R, Miraftab M, Asgari S. Femtosecond laser-assisted LASIK versus PK for high myopia: comparison of 18-month visual acuity and quality. Int Ophthalmol 2017;37:995–1001.
[27] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[28] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.